
The study aims to describe baseline characteristics and follow‐up data in patients with lipodystrophy syndromes treated with metreleptin in a national reference network in a real‐life setting. Clinical and metabolic data from patients receiving metreleptin in France were retrospectively collected at baseline, one year and the latest follow‐up during treatment. Forty‐seven patients with lipodystrophy including generalized lipodystrophy (GLD, n=28) and partial lipodystrophy (PLD, n=19) received metreleptin over the last decade. At baseline, 94% of patients had diabetes (66% insulin‐treated), 53% hypertension, and 87% dyslipidemia. However, among PLD patients, at one year, 61 % were responders regarding glucose homeostasis, with lower baseline leptin levels than non‐responders, and 61% were responders regarding triglyceridemia. Liver enzymes significantly decreased only in the GLD group.
Like
Save
Share